Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
暂无分享,去创建一个
[1] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[2] P. Mitchell,et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. , 2004, Archives of ophthalmology.
[3] Seung-Young Yu,et al. RETINAL TOXICITY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE: A Morphological Study , 2006, Retina.
[4] N. Ferrara,et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.
[5] L. Aiello,et al. RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.
[6] G. Palade,et al. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.
[7] J. Stone,et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.
[8] L. Aiello,et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. , 1995, Archives of ophthalmology.
[9] H. Hammes,et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor–type integrins inhibits retinal neovascularization , 1996, Nature Medicine.
[10] W R Green,et al. Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.
[11] J D Gass,et al. Pathogenesis of disciform detachment of the neuroepithelium. , 1967, American journal of ophthalmology.
[12] T. Cox,et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants , 2003, The British journal of ophthalmology.
[13] Y. Tabata,et al. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. , 2001, Investigative ophthalmology & visual science.
[14] J. Wolfe,et al. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. , 2004, Experimental eye research.
[15] Joan W. Miller,et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.
[16] B. Sullenger,et al. Developing aptamers into therapeutics. , 2000, The Journal of clinical investigation.
[17] P. Campochiaro,et al. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[18] K Miyamoto,et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). , 2000, The American journal of pathology.
[19] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[20] J. Jonas,et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study , 2005, Eye.
[21] P. Campochiaro,et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. , 2002, The American journal of pathology.
[22] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[23] P. Wiedemann,et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.
[24] P. Campochiaro,et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. , 2002, Investigative ophthalmology & visual science.
[25] P. Campochiaro,et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). , 2001, Human gene therapy.
[26] Peter Carmeliet,et al. VEGF: a critical player in neurodegeneration. , 2004, The Journal of clinical investigation.
[27] G. Lutty,et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. , 2002, American journal of ophthalmology.
[28] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[29] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[30] J. Heier,et al. RhuFab V2 in Wet AMD – 6 Month Continued Improvement Following Multiple Intravitreal Injections , 2003 .
[31] K. Jin,et al. Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal , 2000, Journal of Molecular Neuroscience.
[32] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[33] P. Mitchell,et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. , 2003, Archives of ophthalmology.
[34] H. Grossniklaus,et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. , 2002, Molecular vision.
[35] C. Pang,et al. Cytotoxicity of Triamcinolone on Cultured Human Retinal Pigment Epithelial Cells: Comparison with Dexamethasone and Hydrocortisone , 2004, Japanese Journal of Ophthalmology.
[36] Emmett T. Cunningham,et al. VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .
[37] Lawrence A. Yannuzzi,et al. PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[38] M. Matsumura,et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. , 2002, American journal of ophthalmology.
[39] R. Danis,et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. , 1996, Ophthalmology.
[40] A. Adamis,et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. , 1998, Investigative ophthalmology & visual science.
[41] P. Penfold,et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. , 1995, Australian and New Zealand journal of ophthalmology.
[42] R. Danis,et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. , 2001, Archives of ophthalmology.
[43] P. Kaiser,et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. , 2003, American journal of ophthalmology.
[44] D. Eliott,et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.
[45] Sonia H Yoo,et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. , 2003, Survey of ophthalmology.
[46] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[47] Y. Tano,et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. , 2000, American journal of ophthalmology.
[48] C. Dohlman,et al. Posterior subcapsular cataracts induced by topical corticosteroids following keratoplasty for keratoconus. , 1981, Annals of Ophthalmology.
[49] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[50] D. Hinton,et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.
[51] J. Provis,et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. , 2002, Investigative ophthalmology & visual science.
[52] C. Regillo,et al. INFECTIOUS AND PRESUMED NONINFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL TRIAMCINOLONE ACETONIDE INJECTION , 2003, Retina.
[53] J. Park,et al. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.
[54] M. P. Hartmann,et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. , 1994, Current eye research.
[55] H. Redmond,et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1 , 1998, Annals of Surgical Oncology.
[56] O. Volpert,et al. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. , 2002, American journal of ophthalmology.
[57] Z. Werb,et al. Regulation of matrix biology by matrix metalloproteinases. , 2004, Current opinion in cell biology.
[58] J. Slakter,et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. , 2003, Ophthalmology.
[59] A. Reiner,et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.
[60] A Kijlstra,et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. , 1999, American Journal of Pathology.
[61] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[62] D. Connolly,et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.
[63] C. K. Chan,et al. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. , 2001, Human gene therapy.
[64] M. F. Armaly. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE. , 1963, Archives of ophthalmology.
[65] A. Tsujikawa,et al. CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. , 2000, The American journal of pathology.
[66] P. Campochiaro,et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. , 1998, The American journal of pathology.
[67] I J Constable,et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. , 2000, The American journal of pathology.
[68] M. Gillies,et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. , 1998, Australian and New Zealand journal of ophthalmology.
[69] H. Agostini,et al. Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.
[70] P. Campochiaro,et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. , 2004, American journal of ophthalmology.
[71] E S Gragoudas,et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.
[72] G. Lundborg,et al. Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.
[73] J. Slakter,et al. ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy , 2003, Retina.
[74] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[75] J. Sorenson,et al. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. , 2003, Ophthalmology.
[76] H. Ueno,et al. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration , 2000, Gene Therapy.
[77] John I. Loewenstein,et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.
[78] Greene Wr. Histopathology of age-related macular degeneration. , 1999, Molecular vision.
[79] G. Garcı́a-Cardeña,et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.
[80] H. Takagi,et al. Expressions of Angiopoietins and Tie2 in Human Choroidal Neovascular Membranes , 2022 .
[81] M. Komada,et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.
[82] Joan W. Miller,et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. , 2003, Investigative ophthalmology & visual science.
[83] E. Duh,et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. , 2004, Investigative ophthalmology & visual science.
[84] D. Rifkin,et al. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis , 1993, Journal of cellular physiology.
[85] J. Isner,et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.
[86] D. D’Amico,et al. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. , 1992, Archives of ophthalmology.
[87] H. Hammes,et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. , 2001, Diabetes.
[88] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[89] D. Bok,et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[90] Michael D. Ober,et al. Intravitreal triamcinolone acetonide and intraocular pressure. , 2004, American journal of ophthalmology.
[91] M. Shibuya,et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.
[92] J. Rakic,et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[93] Jonathan D. Walker,et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications , 2004, Current opinion in ophthalmology.
[94] R. D'Amato,et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. , 2001, The American journal of pathology.
[95] V. Rajaratnam,et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. , 2001, Investigative ophthalmology & visual science.
[96] W. Benedict,et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.
[97] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[98] J. Ambati,et al. Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[99] Susumu Ishida,et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. , 2004, Investigative ophthalmology & visual science.
[100] Joan W. Miller,et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.
[101] Joan W. Miller,et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. , 2004, Archives of ophthalmology.
[102] Jian-xing Ma,et al. Unbalanced expression of VEGF and PEDF in ischemia‐induced retinal neovascularization , 2001, FEBS letters.
[103] J L Edelman,et al. Quantitative image analysis of laser-induced choroidal neovascularization in rat. , 2000, Experimental eye research.
[104] M. Hartnett,et al. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. , 2004, Molecular vision.
[105] Tom Chang,et al. longitudinal changes in self–reported visual functioningin AMD patients In a randomized controlled Phase I/II trial of lucentisTM (ranizumab; rHuFAB v2) , 2004 .
[106] D. Shima,et al. VEGF–mediated neuroprotection in ischemic retina , 2004 .
[107] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[108] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[109] N. Bouck,et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[110] K. Csaky,et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. , 2000, Investigative ophthalmology & visual science.
[111] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[112] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[113] Joan W. Miller,et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.
[114] K. Yamashiro,et al. VEGF164 is proinflammatory in the diabetic retina. , 2003, Investigative ophthalmology & visual science.
[115] Joan W. Miller,et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.
[116] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[117] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[118] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[119] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.